Cell-surface tissue factor (TF) binds the serine protease factor VIIa to activate coagulation or, alternatively, to trigger signaling through the G protein-coupled, protease-activated receptor 2 (PAR2) relevant to inflammation and angiogenesis. Here we demonstrate that TF⅐VIIa-mediated coagulation and cell signaling involve distinct cellular pools of TF. The surface-accessible, extracellular Cys 186 -Cys 209 disulfide bond of TF is critical for coagulation, and protein disulfide isomerase (PDI) disables coagulation by targeting this disulfide. A TF mutant (TF C209A) with an unpaired Cys 186 retains TF⅐VIIa signaling activity, and it has reduced affinity for VIIa, a characteristic of signaling TF on cells with constitutive TF expression. We further show that PDI suppresses TF coagulant activity in a nitric oxide-dependent pathway, linking the regulation of TF thrombogenicity to oxidative stress in the vasculature. Furthermore, a unique monoclonal antibody recognizes only the noncoagulant, cryptic conformation of TF. This antibody inhibits formation of the TF⅐PAR2 complex and TF⅐VIIa signaling, but it does not prevent coagulation activation. These experiments delineate an upstream regulatory mechanism that controls TF function, and they provide initial evidence that TF⅐VIIa signaling can be specifically inhibited with minimal effects on coagulation.
C
oagulation activation and platelet deposition are increasingly recognized as important events in inflammation, cancer, and angiogenesis. Tissue factor (TF), a member of the cytokine receptor family, binds and allosterically activates factor VIIa. The enzymatic TF⅐VIIa complex then recruits substrate factor X in the ternary TF⅐VIIa⅐X coagulation-initiation complex (1) to generate Xa and ultimately thrombin required for physiological hemostasis (2) . The TF⅐VIIa complex also directly cleaves protease-activated receptor 2 (PAR2) (3, 4) and thus contributes to nonhemostatic roles of the TF pathway in cancer and inflammation (5, 6) . Although PAR2 has been identified as the target for a number of proteases (7) , the link between TF and PAR2 appears to be close. The TF cytoplasmic domain is specifically phosphorylated downstream of PAR2 signaling (8) , and TF cytoplasmic domain-deleted mice display a proangiogenic phenotype dependent on PAR2 (9) .
Fundamentally, it was not clear how the concomitant coagulation activation and thrombin generation would allow for physiologically meaningful direct signaling by the TF⅐VIIa complex. TF is known to be present in a noncoagulant or ''cryptic'' form on the cell surface, but whether the noncoagulant pool is involved in TF⅐VIIa signaling is unknown (10) . In part, cryptic TF is sequestered from lipids that support coagulation reactions, but the absence of procoagulant lipids cannot entirely account for the significantly reduced affinity of TF for VIIa that is documented in cell-signaling experiments (11) . Therefore, TF may have alternative conformations with distinct functional properties. Here, we provide insight into these open questions by identifying disulfide exchange mediated by extracellular protein disulfide isomerase (PDI) as a regulatory mechanism that switches TF between coagulation and TF⅐VIIa signaling. We further describe a monoclonal antibody that binds to the noncoagulant conformation and inhibits TF⅐VIIa signaling by preventing formation of the TF⅐PAR2 complex. Thus, it is feasible to block TF⅐VIIa signaling without compromising TF-dependent hemostasis.
Results

Different Cellular Pools of TF Mediate Coagulation Activation and
TF⅐VIIa Signaling. To address the regulation of TF functions in coagulation and signaling, we focused on a cell model with constitutive TF expression. We found that the coagulant activity of TF remained unchanged despite progressive loss of TF expression to Ͻ5% in human HaCaT keratinocytes during growth arrest (Fig. 1A) . A set of antibodies for distinct epitopes was used to evaluate TF expression on the cell surface. mAb 9C3 binds close to the VIIa-binding site, whereas mAb 5G9 inhibits coagulation by competing with substrate factor X binding (12, 13) . mAb 10H10 and mAb 5G9 do not inhibit VIIa binding, and they bind to partially overlapping epitopes, but mAb 10H10 does not block coagulation activation. Staining of nonpermeabilized cells with mAb 9C3 or 5G9 (Fig. 1B) or surface biotinylation (data not shown) indicated that cell-surface expression, rather than intracellular pools of TF, changed during growth arrest. Inhibition of coagulation by mAb 5G9 was independent of time of culture (Fig. 1C) . Unexpectedly, mAb 10H10 lost reactivity with the remaining coagulant pool of TF at day 5 (Fig. 1B) . Furthermore, immobilized mAb 10H10 depleted Ͻ20% and mAb 5G9 Ͼ85% of the coagulant activity from a preparation of phospholipid-reconstituted, purified TF (Fig. 1D ). Taken together, these data indicate that mAb 10H10 has low affinity for the minor cellular pool of coagulant TF but recognizes cryptic pools of TF.
Unlike coagulant activity, TF⅐VIIa signaling gradually decreased from day 1 to day 6 (Fig. 1E) . TF⅐VIIa signaling on these cells was PAR2-dependent, but PAR2 activation with the direct agonist SLIGRL or thrombin signaling was unchanged during prolonged culture (Fig. 1F) . Cell-surface-expressed TF binds VIIa with variable affinity (14) , and TF-dependent Xa generation is saturated at lower VIIa concentrations relative to TF⅐VIIa signaling (15) . Irrespective of time of culture, coagulant TF on cells had high affinity for VIIa because rates of Xa generation were saturated to Ϸ99% at 1 nM VIIa. Only high (10 nM) but not low (1 nM) concentrations of VIIa induced signaling by the binary TF⅐VIIa complex on cells at day 1 (Fig. 1G) , and the addition of a potent Xa inhibitor (NAP5) excluded signaling by other downstream coagulation factors. Importantly, mAb 10H10, with poor reactivity toward coagulant TF, efficiently blocked TF⅐VIIa signaling. Although mAb 5G9 was reactive with coagulant and noncoagulant pools of TF on cells ( Fig. 1 A and  B) , TF⅐VIIa signaling was not inhibited by this antibody.
In addition to direct cleavage of PAR2 by the TF⅐VIIa complex, TF also serves as a scaffold to assemble the ternary TF⅐VIIa⅐X coagulation complex in which nascent product Xa signals by activating PARs (4). One nanomolar VIIa was sufficient for TF⅐VIIa⅐Xa signaling that was blocked by the Xa inhibitor NAP5 and by mAb 5G9, which blocks the substrate X-binding site on TF (Fig. 1G) . mAb 10H10 did not block ternary TF⅐VIIa⅐Xa complex signaling, consistent with its poor affinity for coagulant TF. Thus, antigenically distinct pools of TF are responsible for coagulation activation versus TF⅐VIIa signaling, and the inhibitory profile of mAb 10H10 shows that TF⅐VIIa signaling can be blocked with minimal effects on coagulation.
Redox State of the TF Cys 186 -Cys 209 Disulfide Determines TF⅐VIIa Signaling Specificity. We reasoned that a conformational change in TF is responsible for differences in VIIa affinity, and we focused on the exposed TF Cys 186 -Cys 209 disulfide bond, which is required for coagulation activation (16) . The Cys 186 -Cys 209 disulfide is solvent-exposed, and such cross-strand disulfides between parallel ␤-strands are less stable because of the strained bond geometry (17) (18) (19) . Alanine substitution mutants for Cys 186 or Cys 209 were expressed by adenoviral transduction of human umbilical vein endothelial cells (HUVECs) to surface levels similar to wild-type TF, based on flow cytometry or mAb 9C3 staining ( Fig. 2A) . Each mutant showed Ͼ95% diminished TF⅐VIIa-mediated Xa generation. TF⅐VIIa signaling appeared normal with C209A, but no signaling was detectable with C186A TF (Fig. 2B ). Dose-response curves showed that TF⅐VIIa signaling in wild-type TF-expressing cells required 1 nM VIIa or more, but TF⅐VIIa⅐Xa signaling was saturated at this concentration of VIIa (Fig. 2C) . With C209A TF, TF⅐VIIa signaling required slightly lower concentrations of VIIa relative to wildtype TF, but C209A TF-mediated signaling did not change when substrate X was added. Thus, formation of the Cys 186 -Cys 209 disulfide is required to generate TF with high affinity for VIIa, full coagulant activity, and concomitant ternary TF⅐VIIa⅐Xa complex signaling.
Expression of soluble C209A TF yielded both monomers and dimers, but purified dimers were inactive in a chromogenic assay that measures the allosteric induction of VIIa catalytic activity. In contrast, monomeric soluble C209A TF activated VIIa, but with diminished affinity relative to wild-type TF (Fig. 2D) . Thus, breaking of the Cys 186 -Cys 209 disulfide reduces affinity for VIIa; but at saturation, C209A TF fully activated VIIa, which is necessary for proteolytic cell signaling through PAR2. C209A appears to be prone to mixed disulfide formation, and surface biotinylation showed a large fraction of C209A TF in a cellsurface SDS-stable dimer (Fig. 2E) . The molecular weight of the surface C209A TF dimer differed from that in intracellular pools, but after deglycosylation the mobility was similar (data not shown). Consistent with formation of a C209A TF homodimer on the cell surface, Western blotting of TF immunoprecipitates PAR2 dependence of TF⅐VIIa signaling. (G) mAb 10H10 specifically inhibits TF⅐VIIa signaling. Different affinity for VIIa distinguishes TF that mediates TF⅐VIIa or ternary TF⅐VIIa⅐Xa complex signaling. At 1 nM VIIa, cells display only Xa-dependent TF⅐VIIa⅐Xa signaling that is inhibited by the specific Xa inhibitor nematode anticoagulant protein 5 (NAP5) or mAb 5G9. At 10 nM VIIa, direct signaling of TF⅐VIIa occurs that is not inhibited by NAP5 or mAb 5G9 but is blocked by mAb 10H10. ERK phosphorylation at 10 min was quantified (mean Ϯ SD; n Ͼ 3). for PAR2 further excluded the formation of an SDS-stable heterodimer with PAR2 (Fig. 2E) . Because the purified C209A dimer was inactive, we conclude that the small pool of monomeric, cell-surface-expressed C209A TF mediated cell signaling.
TF⅐VIIa signaling of wild-type or C209A TF-expressing cells required PAR2 cotransduction, and it was blocked by anti-PAR2 antibody. Although PAR2 and C209A TF did not form an SDS-stable complex, both mutant and wild-type TF similarly coimmunoprecipitated PAR2. The degree of PAR2 complex formation was consistent with the similar TF⅐VIIa signaling activity of C209A versus wild-type TF. Our PAR2 antibody recognizes the activation region of PAR2. Pretreatment of cells with VIIa for 10 min abolished PAR2 detection in C209A TF immunoprecipitates (Fig. 2F) , indicating that the immunoprecipitated pool of PAR2 is cleaved on the cell surface and participates in cell signaling. Although wild-type TF was expressed at 50-to 100-fold higher cell-surface levels than monomeric C209A TF, TF⅐VIIa signaling was not different between mutant and wild-type TF in the depicted MAP kinase phosphorylation assay (Fig. 2B) or gene-induction readouts, such as TR3 up-regulation (20) (data not shown). We conclude from these findings that only a minor fraction of wild-type TF is present in a PAR2-signaling complex and that high cell-surface TF expression levels are not required for efficient TF⅐VIIa signaling.
mAb 10H10 had poor reactivity for surface pools of C209A TF, but it efficiently immunoprecipitated intracellular pools (Fig. 2E) . Unlike wild-type TF⅐VIIa signaling, mAb 10H10 did not block C209A TF signaling (Fig. 2G ), indicating that inhibition of signaling is through targeting of extracellular pools of TF. We hypothesized that dynamic disulfide͞thiol exchange generated signaling-active wild-type TF, whereas the small surface pool of monomeric C209A TF was in a more stable, slowly exchanging linkage with PAR2. Pretreatment of cells with the relative membrane-impermeant thiol blocker N ␣ -(3-maleimidylpropionyl)biocytin (MPB) inhibited wild-type TF⅐VIIa but not C209A TF⅐VIIa signaling (Fig. 2G) . Importantly, MPB pretreatment blocked neither direct PAR2 agonist responses nor signaling of the ternary wild-type TF⅐VIIa⅐Xa complex, which requires TF with an intact Cys 186 -Cys 209 disulfide. Thus, only TF⅐VIIa signaling is sensitive to extracellular thiol blockade.
Association of PDI with TF. To address cellular mechanisms by which the TF disulfide is broken, we established conditions that modulate TF function without changing constitutive expression of TF in HaCaT cells. Cells were seeded into Ca 2ϩ -depleted medium to prevent cell-cell contacts for 48 h. Alternatively, medium was supplemented for the last 24 h with 2 mM Ca 2ϩ (high Ca 2ϩ ), which induced distinct epithelial morphology as expected. mAb 9C3 immunoprecipitated equivalent amounts of surface-biotinylated TF under both conditions. Similar cellsurface expression and lack of significant intracellular pools were further confirmed by pulldown with mAb 5G9, which does not immunoprecipitate TF after cell-surface biotinylation (Fig. 3A) . For functional assays, cells were equilibrated for 10 min in serum-free medium containing Ca 2ϩ to support coagulation and signaling reactions. TF showed marked functional differences under the two culture conditions (Fig. 3B) . Coagulant activity was Ϸ3-to 6-fold higher in low-Ca 2ϩ cells, whereas TF⅐VIIa signaling was detectable only in high-, but not low-, Ca 2ϩ cells. Direct PAR2 activation with agonist peptide was comparable under both conditions, excluding loss of PAR2 signaling. Thus, the cell-surface environment of high-Ca 2ϩ cells favored TF signaling while disabling coagulation.
We hypothesized that a reductive PDI pathway targets the TF Cys 186 -Cys 209 disulfide bond to suppress coagulation. MPBlabeling yielded coprecipitating thiol-biotinylated bands of Ϸ56 and 64 kDa in mAb 9C3 pulldowns specifically from high-Ca 2ϩ cells (Fig. 3C) . Blocking vicinal thiols with PAO abolished labeling of these bands, but a faint labeled band at the appropriate molecular mass for TF became somewhat more prominent. Anti-PDI also precipitated MPB-labeled bands of 56 and 64 kDa (Fig. 3D ), but the 56-kDa species was typically only a minor fraction in PDI immunoprecipitates. We considered whether the 56-kDa band was the close PDI homolog ERP57, but ERP57 knockdown with siRNA demonstrated that bands coprecipitating with TF were not ERP57, but instead they depended on high levels of PDI expression (Fig. 3D) . Western blotting showed that PDI association with TF immunoprecipitates was increased in high-versus low-Ca 2ϩ cells, and NHS surface biotinylation confirmed that PDI association with TF was extracellular (Fig. 3E) . Thus, PDI is associated with TF on the cell surface when coagulant activity is low and TF⅐VIIa signaling is enabled. dissociated MPB-labeled PDI from TF, and it also abolished staining with cryptic TF-specific mAb 10H10. TF cell-surface expression based on mAb 9C3 staining (Fig. 4A ) or surface biotinylation (data not shown) did not change. Exposure to Hg 2ϩ further restored coagulant activity of high-Ca 2ϩ cells to levels that were comparable to low-Ca 2ϩ cells (Fig. 4B) . Hg 2ϩ had minimal effects on TF coagulant activity of low-Ca 2ϩ cells, indicating that Hg 2ϩ did not increase procoagulant phospholipids under the experimental conditions. Thiol blockade with 50 mM methyl methanethiolsulfonate (MMTS) did not change baseline TF activity, but it did reduce the Hg 2ϩ effect on TF activity from 5-to 6-fold to Ͻ2-fold. MMTS blocked free thiols of surface PDI, indicating that PDI is required for the activating effect of Hg 2ϩ . PDI expression was reduced by siRNA to 32 Ϯ 13% of control levels, based on Western blotting. Decreased PDI expression was associated with an Ϸ2-fold increase of TF coagulant activity (Fig. 4B) . Importantly, after Hg 2ϩ activation, TF procoagulant activity was similar in siRNA-treated cells and controls. These data provide additional evidence that Hg 2ϩ selectively reversed PDI-mediated suppression of TF procoagulant function.
The mutational analysis showed that breaking the Cys 186 -Cys 209 disulfide renders TF coagulation inactive, but MPB labeling showed no prominent free thiols of TF on high-Ca 2ϩ cells. Cell-surface PDI catalyzes transnitrosylation and denitrosylation reactions (21, 22) , and PDI can be S-nitrosylated at vicinal thiols (23) . Fifty to 100 M Hg 2ϩ was required to enhance TF coagulant activity, which is typical of the concentrations needed to release nitric oxide (NO) from PDI (23), raising the possibility that the activating effect of Hg 2ϩ involved denitrosylation of PDI. The biotin-switch method (24) was used to detect S-nitrosylation. After blocking cellular free thiols with Nethylmaleimide, cells were MPB-labeled in the presence or absence of ascorbic acid to release NO. With specificity for high-Ca 2ϩ cells, immunoprecipitated PDI showed increased MPB labeling in the presence of ascorbic acid (Fig. 4C) . MPBlabeled bands at the appropriate molecular mass for TF also became visible in PDI immunoprecipitates. Similarly, after blockade of free thiols with 1 mM iodoacetamide, MPB labeling of TF immunoprecipitates significantly increased in the presence of ascorbic acid (Fig. 4D) . These data indicated that inactivation of TF coagulant activity depends on NO.
We tested whether Hg 2ϩ -induced activation of TF was reversible. After washout of the oxidant, coagulant activity of TF remained high. The addition of reduced GSH or the NO donor SNP alone had no effect on TF activity, but in combination TF coagulant activity was suppressed (Fig. 4E) . The vicinal thiol PDI but not ERP57 knockdown with siRNA prevents MPB-labeled bands in TF immunoprecipitates. (E) NHS surface-biotinylated PDI is specifically associated with high-Ca 2ϩ cells. The PDI inhibitor bacitracin (3 mM) also dissociates PDI from TF in mAb 9C3 immunoprecipitates, but it has no effect on low-Ca 2ϩ cells. blocker PAO prevented inactivation of TF, indicating involvement of PDI to break the TF disulfide. NO reacts with GSH to yield GSNO, and the addition of GSNO was sufficient to suppress TF coagulant activity. A detailed biochemical analysis will be required to define which thiols in TF are susceptible to S-nitrosylation and whether the breakdown of GSNO yields glutathionation as an alternative modification of TF as well.
Complex Formation with PAR2 Is Required for TF⅐VIIa Signaling. mAb 5G9 had no effect on TF⅐VIIa signaling, but it showed strong reactivity with coagulant and noncoagulant pools of TF. This antibody immunoprecipitated a complex of TF with PAR2 from HaCaT cells (Fig. 5A) . Hg 2ϩ treatment to release surface PDI from TF abolished PAR2 complex formation with TF in mAb 5G9 immunoprecipitates. Pretreatment of cells with mAb 5G9 had no effect on the reverse association of TF with PAR2 immunoprecipitates, but the signaling blocking mAb 10H10 significantly reduced TF-PAR2 association (Fig. 5B) . Thus, antibody blockade of TF⅐VIIa signaling was correlated with reduced TF⅐PAR2 coimmunoprecipitation. Unlike mAb 5G9, mAb 10H10 did not immunoprecipitate PAR2 (Fig. 5C) or PDI (Fig. 5D ), indicating that this antibody prevents the formation of a complex involving TF, PAR2, and PDI.
Complete knockdown of PDI by siRNA was not achievable. We therefore inhibited PDI with bacitracin which, at 2-3 mM, is widely used to block cell-surface PDI function (25) . Bacitracin was repurified to eliminate known enzymatic contaminants (26) . To evaluate the effect of bacitracin on TF-PDI association, HaCaT cells were treated for 10 min with bacitracin followed by MPB labeling and TF immunoprecipitation with mAb 9C3. Bacitracin significantly reduced TF-associated PDI detected by Western blotting or MPB labeling (Fig. 5E ). Cells were pretreated with bacitracin but then placed for an additional 10 min in serum-free medium. PDI reassociated with TF under this scheme. In the presence of bacitracin, TF⅐VIIa signaling was inhibited, but bacitracin did not block direct PAR2 agonist or thrombin signaling, demonstrating specificity (Fig. 5F) . Washout experiments that resulted in PDI reassociation with TF (Fig. 5E ) completely reversed the inhibitory effect of bacitracin on TF⅐VIIa signaling. Taken together, these data show in a cellular model with physiological levels of TF and PAR2 that PDI acts as a regulatory switch between direct TF⅐VIIa cell signaling and coagulation activation.
Discussion
The present data provide insight into the regulation of TF function on cells. By mutation, we show that the extracellular Cys 186 -Cys 209 disulfide bond is required for coagulationactivation as well as coagulation-initiation phase signaling by Xa in the ternary TF⅐VIIa⅐Xa complex but not for direct PAR2 cleavage by the binary TF⅐VIIa complex. Mutational breaking of this disulfide recapitulates the functional properties of the TF⅐VIIa signaling pool, which has low affinity for VIIa on cells with constitutive TF expression. We further demonstrate that TF coagulant activity is suppressed during association of extracellular PDI with TF and that disulfide͞thiol-exchange pathways are required for TF⅐PAR2 complex formation and TF⅐VIIa signaling. These data delineate the biochemical mechanism by which TF⅐VIIa is switched from coagulation to direct cell signaling and thus provide a solution to the fundamental problem of how TF⅐VIIa signaling can occur independently of coagulation activation.
Our study adds an unexpected aspect to the biology of extracellular disulfide-exchange pathways by demonstrating versatility to switch a single receptor between two distinct biological activities. Disulfide͞thiol exchange is an allosteric mechanism to control extracellular proteolysis, matrix remodeling, and cell adhesion, and S-nitrosylation has been demonstrated to regulate integrin activation (27) (28) (29) (30) (31) (32) . The presented data indicate that breaking of the Cys 186 -Cys 209 disulfide bond to inhibit TF coagulant function is similarly under the control of NO pathways. Vascular-protective NO synthesis is frequently perturbed in atherosclerosis, diabetes, or inf lammation (33) , and uncoupling of NO synthesis may shift cellsurface TF activity to coagulation. NO-dependent inhibition of TF coagulant activity thus links the regulation of thrombogenicity in an unexpected way to oxidative stress in cardiovascular disease and inf lammation.
The biochemical evidence for a switch in TF functional specificity is further corroborated by conformational changes detected by mAb 10H10. mAb 10H10 has low affinity for coagulant TF, but it binds the noncoagulant, cryptic pool of TF efficiently. mAb 10H10 either prevents formation or actually disrupts the TF⅐PAR2 complex and thus inhibits TF⅐VIIa signaling. This finding implies the existence of a pool of signaling TF that is distinct from other noncoagulant pools. From the low expression levels of monomeric C209A TF we deduce that a small fraction of TF is sufficient for TF⅐VIIa signaling, but at present there is no antibody that reacts selectively with the complex of TF with PAR2 without recognizing other pools. PDI and thiol pathways are critical for TF⅐VIIa signaling, and we found a close correlation between TF-PDI association and TF⅐VIIa signaling in several cell types, including breast cancer cells. Preliminary experiments further demonstrate that blockade of TF⅐VIIa signaling in these cells by mAb 10H10 is superior to blocking coagulation by mAb 5G9 to suppress tumor growth, emphasizing the relevance of the TF⅐VIIa signaling pathway in vivo. Importantly, mAb 10H10 has minimal effects on coagulation activation, providing initial evidence that inhibition of TF⅐VIIa signaling is feasible without impairing hemostasis. nM VIIa. * , P Ͻ 0.01 relative to control (t test; mean Ϯ SD; n Ͼ 4).
